newsfilter
← Latest News
Business Wire·

Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update

Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R2 Epizyme (NASDAQ:EPZM), a fully integrated,